The findings suggest a new approach to clearing infections from AIDS to hepatitis

15-04-2013

Scientists at The Scripps Research Institute (TSRI) have made a counterintuitive finding that may lead to new ways to clear persistent infection that is the hallmark of such diseases as AIDS, hepatitis B and hepatitis C. The study, reported in the journal Science, focused on the activity of ...

more

Promising therapeutic approach for humans

28-11-2012

Alzheimer's disease is one of the most common causes of dementia.The accumulation of particular abnormal proteins, including amyloid-ß (Aβ) among others, in patients' brains plays a central role in this disease. Prof. Frank Heppner from the Department of Neuropathology at Charité and his ...

more

06-11-2012

Researchers at Tokyo Institute of Technology and the Weizmann Institute of Science identify a means of controlling biological processes that could help treatments for immune disease, neurological disorders and cancer.The cellular response to a number of signals including inflammatory ...

more

03-07-2012

A Swedish research group headed at Karolinska Institutet has been able to prevent onset of Type 1 diabetes in mice that are genetically susceptible to the disease. Through injection of specifically prepared cells, the researchers managed to stop the ongoing destruction of insulin-producing ...

more

19-12-2011

NovImmune announced that Genentech, a member of the Roche Group, initiated a First-in-Human study with anti-IL-17 (NI-1401, RG7624), a fully human monoclonal antibody designed to specifically and selectively bind to the human IL-17 family of cytokines. The anti-IL-17 antibody was generated at ...

more

20-09-2011

AMSBIO has announced a pan European partnership with Chondrex Inc. to market their high quality arthritis and inflammation reagents to academics and pharmaceutical companies that do research in these fields.The range includes a suite of high quality reagents such as highly purified cartilage ...

more

Merck Serono to develop compounds from Affectis targeting P2X7 receptors

10-06-2011

Affectis Pharmaceuticals AG announced that an exclusive licensing agreement was signed with Merck Serono, a division of Merck KGaA, for the development and commercialization of oral compounds targeting P2X7 receptors. These receptors are believed to be involved in neuroinflammation observed ...

more

29-11-2010

Scientists at Gladstone Institute of Virology and Immunology have solved a long-standing mystery about HIV infection–namely how HIV promotes the death of CD4 T cells. It is the loss of this critical subset of immune cells that leads to the development of AIDS. Most immune cells that die ...

more

03-11-2010

Karus Therapeutics Ltd has commenced preclinical development of its HDAC6 and PI3-Kinase inhibitor programmes for the treatment of immune and inflammatory diseases such as rheumatoid arthritis (RA). Karus aims to initiate clinical trials for both programmes in 2011. Karus’s highly potent ...

more

25-08-2010

PBL InterferonSource announced that its founder and chief scientific officer (CSO), Sidney Pestka, M.D., will receive the 'Distinguished Service Award' from the International Society for Interferon and Cytokine Research (ISICR) at the ISICR's annual meeting on October 3-7, 2010, in ...

more